logologologologo
  • SERVICES
    • HOW IT WORKS
    • COSMETIC CRYO-FAT PROGRAM
    • ADULT STEM CELL PROGRAMS
  • PRODUCTS
    • TISSUE HARVESTING SYSTEM
    • STEM CELL MEDIAS
    • STEM CELL LINES
  • INVESTORS
    • ABOUT US
    • STOCK INFORMATION
    • PRESS RELEASES
    • OUR LEADERSHIP
    • LICENSING PARTNERS
  • NEWS
  • CONTACT US

American CryoStem to Exhibit at the Aesthetic Meeting

April 11, 2013

Eatontown, NJ – (GlobeNewswire) – April 11, 2013 – American CryoStem Corporation (OTCQB: CRYO), a leading biotech company in the field of Regenerative Medicine, today announced that the Company is scheduled to exhibit at The Aesthetic Meeting 2013, held this week, April 11-16th in New York City, at the Jacob Javits Convention Center. The Company will be showcasing its latest adipose tissue (fat) collection, processing and storage service, ATGRAFT™ and complimentary personalized skin care products. With one liposuction, ATGRAFT™ is a complete fat tissue storage solution for physicians to perform layered fat transfers and provides patients additional opportunities to use their stored fat tissue to create personalized skin care products or clinically processed stem cells for use in Regenerative Medicine treatments.

This premier event for surgeons, is to learn and be updated on the latest; news, technologies and trends in the cosmetic industry. These informative sessions are straight from plastic surgeons that specialize in aesthetic plastic surgery and are on the cutting edge of new technologies and methodologies. This year is especially poignant and effective, offering the hottest topics and procedures in the industry. The week entails; ideas in improvement in patient safety, overall efficiency, with innovative practice and skill enhancements. The Aesthetic Meeting is hosted by the American Society for Aesthetic Plastic Surgery (ASAPS), and will disclose some of the most exciting new developments in the fields of health and beauty.

If you are a physician and would like to receive information concerning the conference or American CryoStem’s ATGRAFT™ service, please email info@americancryostem.com, or contact John DiFolco at 732-747-1007.

EVENT AT A GLANCE
WHO:American CryoStem Corporation
John Arnone – Chairman and CEO
Anthony Dudzinski – COO

WHEN:Thursday, April 11, 2013 – Tuesday, April 16, 2013

WHERE:Booth #968
Jacob Javits Convention Center
655 W 34th Street
New York, New York 10001

NOTE TO PRESS:The media also is invited to attend the event on a complimentary basis. Please contact; Adeena Babbitt or Ashley Barton at 800-364-2147 or media@surgery.org to register for the event. To arrange one-on-one interviews with the executive management team of American CryoStem, please contact Erin Palmer at Hanover|Elite at 407-585-1080 or via email at CRYO@hanoverelite.com.

About American CryoStem Corporation
A pioneer in the fields of Regenerative and Personalized Medicine, American CryoStem is a developer, marketer and global licensor of patented adipose tissue based cellular technologies and related proprietary services with a focus on clinical processing, commercial bio-banking and application development for adipose (fat) tissue and autologous adipose-derived regenerative cells (ADRCs). The Company maintains a strategic portfolio of intellectual property and patent applications that form its Adipose Tissue Processing Platform, which supports and promotes a growing pipeline of biologic products and processes, clinical services and international licensing opportunities. Through its ACS Laboratories division, the Company operates an FDA registered, cGMP compliant human tissue processing, cryo-storage and cell culture and differentiation media development facility in Mount Laurel, New Jersey. For more information, please visit www.americancryostem.com and www.acslaboratories.com.

Share

Related posts

January 6, 2021

American CryoStem Enters into a Cooperative Research and Development Agreement (CRADA) to Develop Standardized Treatment Protocols


Read more
December 1, 2020

American CryoStem Announces Patient Recruitment and Additional Sub-Investigator for its Post-Concussion Syndrome (PCS) Phase I Clinical Trial


Read more
September 23, 2020

American CryoStem Announces: FDA has cleared its Investigational New Drug (IND) for Post-Concussion Syndrome for Phase I Clinical Trial


Read more

About American CryoStem Corporation

American CryoStem (CRYO) is a leading developer, manufacturer, and marketer of life-enhancing, adipose tissue (fat) based stem cell technologies. The company offers a proprietary tissue collection, processing and cryo-storage platform for (current or future) regenerative medicine applications using adult stem cells to address the impact of aging, injury and other disorders.

© 2018 American CryoStem Corporation | A Publicly Traded Company (CRYO)
  • Physicians
  • Licensing & Partners
  • OTCBB: CRYO